From: Acetazolamide potentiates the anti-tumor potential of HDACi, MS-275, in neuroblastoma
Cell line | Treatment modality | Concentration (μM) | Reduction in cell viability (%) | p value |
---|---|---|---|---|
NSC6539 | AZ | 10 | 6 ± 0.67 | - |
20 | 26 ± 0.87 | p < 0.05 | ||
40 | 47 ± 0.07 | p < 0.01 | ||
MS-275 | 0.75 | 12 ± 0.85 | - | |
1.5 | 32 ± 0.97 | p < 0.05 | ||
3 | 51 ± 0.23 | p < 0.01 | ||
AZ + MS-275 | 10 + 0.75 | 28 ± 0.95 | - | |
20 + 0.75 | 46 ± 0.56 | p < 0.05 | ||
40 + 0.75 | 55 ± 0.50 | p < 0.01 | ||
NSC6562 | AZ | 10 | 2 ± 0.07 | - |
20 | 22 ± 0.47 | p < 0.05 | ||
40 | 45 ± 0.67 | p < 0.01 | ||
MS-275 | 0.75 | 10 ± 0.34 | - | |
1.5 | 24 ± 0.08 | p < 0.05 | ||
3 | 46 ± 0.39 | p < 0.01 | ||
AZ + MS-275 | 10 + 0.75 | 23 ± 0.86 | - | |
20 + 0.75 | 38 ± 0.50 | p < 0.05 | ||
40 + 0.75 | 50 ± 0.61 | p < 0.01 | ||
SH-SY5Y | AZ | 10 | 16 ± 0.20 | p < 0.05 |
20 | 39 ± 0.64 | p < 0.01 | ||
40 | 35 ± 0.58 | p < 0.001 | ||
MS-275 | 0.75 | 32 ± 0.55 | p < 0.001 | |
1.5 | 60 ± 0.69 | p < 0.001 | ||
3 | 86 ± 0.78 | p < 0.001 | ||
AZ + MS-275 | 10 + 0.75 | 35 ± 0.85 | p < 0.01 | |
20 + 0.75 | 55 ± 0.86 | p < 0.001 | ||
40 + 0.75 | 64 ± 0.78 | p < 0.001 | ||
SK-N-SH | AZ | 10 | 22 ± 0.59 | p < 0.01 |
20 | 34 ± 0.42 | p < 0.01 | ||
40 | 61 ± 0.03 | p < 0.001 | ||
MS-275 | 0.75 | 37 ± 0.99 | p < 0.001 | |
1.5 | 66 ± 0.03 | p < 0.001 | ||
3 | 87 ± 0.19 | p < 0.001 | ||
AZ + MS-275 | 10 + 0.75 | 37 ± 0.85 | p < 0.01 | |
20 + 0.75 | 58 ± 0.86 | p < 0.001 | ||
40 + 0.75 | 69 ± 0.95 | p < 0.001 | ||
SK-N-BE(2) | AZ | 10 | 15 ± 0.01 | p < 0.01 |
20 | 37 ± 0.61 | p < 0.01 | ||
40 | 61 ± 0.58 | p < 0.001 | ||
MS-275 | 0.75 | 26 ± 0.69 | p < 0.001 | |
1.5 | 55 ± 0.38 | p < 0.001 | ||
3 | 82 ± 0.21 | p < 0.001 | ||
AZ + MS-275 | 10 + 0.75 | 34 ± 0.88 | p < 0.01 | |
20 + 0.75 | 52 ± 0.88 | p < 0.001 | ||
40 + 0.75 | 62 ± 0.86 | p < 0.001 |